Radiomics is leading a clinical trial entitled "SALMON" ("meaSure lung cAncer bioLogy and treatMent respOnse via imagiNg"), a prospective, interventional, multi-center, multi-country, biomarker validation study, involving 30 healthcare institutions within the EU, to demonstrate the value of AI solutions in 1000 patients with non-small cell lung cancer.
Radiomics other areas



onetrial, two tracks, multiplevaluable solutions

SALMON study tracks


*for further information, please contact us

This study has received funding from SPW  and DG06